天然免疫检查点CD47-SIRPα在恶性肿瘤中的研究进展
DOI: 10.3971/j.issn.1000-8578.2018.18.0217
Keywords: 恶性肿瘤,CD47,SIRPα,免疫检查点,免疫治疗,Research Progress of PD-1/PD-L1 Targeted Radionuclide Molecular Probes in Tumor Immunotherapy,Research Progress of Intestinal Microbiota and Immune Checkpoint Inhibitors,A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer,Advances of 125I Radioactive Particle Chain Intracavitary Brachytherapy,Advances in Molecular Mechanisms of Early Bone Metastasis,Progress on Comprehensive Treatment of Nasopharyngeal Cancer,Research Advances on Small Molecule Targets for Tumor Immunotherapy,Infections of Pathogens in Lesions of Cutaneous Carcinoma,Role of SWI/SNF Complex Subunit Abnormality in Tumors and Progress of Related Therapeutic Strategies,Progress of Molecular Imaging in Diagnosis of HER2 Positive Tumors,Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer,Advances in Metabolic Characteristics of Malignant Tumors and Their Correlation with Inflammatory Mediators,Diagnostic Value of FH Test for Early Screening of Rectal Cancer,Polyinosinic-polycytidylic Acid Mediates PD-1 Expression in T Cells at Early Stage of Activation and Inhibits Melanoma Growth,Research Progress of Formononetin for Anticancer Drug Development
Abstract:
摘要 针对CTLA-4/B7和PD-1/PD-L1的免疫检查点抑制剂现已广泛应用于临床，其他检查点抑制剂也正在开发中。CD47是广泛表达于正常细胞表面的蛋白质，在肿瘤细胞中呈过表达状态，其受体为髓系抑制性免疫受体SIRPα。阻断CD47与SIRPα之间的相互作用可增强巨噬细胞和中性粒细胞的吞噬作用进而消灭肿瘤细胞。此外，越来越多的证据表明阻断CD47-SIRPα轴还可以增强抗原呈递细胞的功能，从而刺激T细胞介导的抗癌免疫。随着该领域研究的发展，CD47-SIRPα轴的临床应用将会是未来肿瘤免疫治疗的热点之一
Full-Text
